Urothelial carcinoma, the most common form of bladder cancer, has entered a new therapeutic era with the arrival of a treatment strategy that attacks tumors on two biological fronts at once. A multi-institutional real-world investigation known as GUARDIANS has examined how enfortumab vedotin combined with pembrolizumab performs outside the carefully controlled environment of a clinical trial. Published in Cancer Immunology, Immunotherapy, the study evaluates both the effectiveness and safety of the combination in patients treated across routine oncology settings, offering a closer look at how a rapidly adopted regimen behaves among the broader and often more medically complex population seen in everyday practice.
Urothelial carcinoma can arise in the bladder, ureters, renal pelvis, or urethra and is frequently diagnosed when it has already invaded surrounding tissue or spread to distant organs. For many years, platinum-based chemotherapy formed the backbone of treatment for advanced disease, but its effectiveness is limited by resistance, relapse, and the health status of patients who may be older or affected by kidney impairment and other illnesses. The combination examined in GUARDIANS brings together two distinctly engineered medicines. Enfortumab vedotin is an antibody–drug conjugate that recognizes Nectin-4, a protein commonly present at high levels on urothelial cancer cells, while pembrolizumab is an immune checkpoint inhibitor that helps restore the capacity of T cells to attack malignant cells.
Enfortumab vedotin operates as a molecular delivery system. Its antibody component binds to Nectin-4 on the tumor-cell surface and is internalized, carrying with it the cytotoxic payload monomethyl auristatin E, or MMAE. Once released inside the cell, MMAE disrupts microtubules, structures required for cell division, eventually triggering cell death. Pembrolizumab works through a different pathway. Tumors can suppress immune activity by engaging the PD-1 receptor on T cells through its ligands, PD-L1 and PD-L2. By blocking PD-1, pembrolizumab can release this inhibitory signal. The combination therefore pairs direct drug-mediated killing with immune reactivation, a strategy that may produce complementary or synergistic antitumor effects.
The importance of the GUARDIANS analysis lies in its real-world design. Randomized trials are essential for establishing whether a treatment works under standardized conditions, but participants in those studies are often selected according to strict criteria involving organ function, performance status, previous therapies, and the absence of serious coexisting disease. Routine clinical practice is less predictable. Physicians treat patients with varying levels of frailty, diverse patterns of metastasis, different prior treatments, and medical conditions that may influence both benefit and toxicity. By assembling data from multiple institutions, the GUARDIANS investigators sought to determine whether the clinical promise of enfortumab vedotin plus pembrolizumab remained visible when the regimen was used across a wider spectrum of patients.
The study’s central assessment focused on effectiveness and safety, the two measures that ultimately determine whether a cancer therapy can be integrated into routine care. Effectiveness in this setting is generally evaluated through outcomes such as tumor response, disease control, progression-free survival, and overall survival. These measures address different questions: whether tumors shrink, how long the cancer remains stable or controlled, how quickly the disease progresses, and how long patients live after treatment begins. Safety analysis examines treatment-related adverse events, dose interruptions, reductions, and discontinuations. Such details are particularly important for a combination in which adverse effects can arise from either the antibody–drug conjugate, the immune therapy, or the interaction between treatment and a patient’s underlying vulnerabilities.
The findings provide real-world support for the clinical activity of the combination in advanced urothelial carcinoma, while also illustrating the practical toxicities that oncologists must manage. The regimen is not a simple infusion with a uniform risk profile. Enfortumab vedotin can be associated with peripheral neuropathy, skin reactions, fatigue, appetite changes, hyperglycemia, and ocular complications, reflecting the effects of its cytotoxic payload and its distribution through the body. Pembrolizumab can produce immune-related inflammation affecting organs such as the thyroid, lungs, liver, colon, kidneys, or skin. These reactions occur when immune activation extends beyond the tumor and can require corticosteroids, treatment interruption, or permanent discontinuation in serious cases.
The real-world perspective is especially relevant for patients who would not necessarily resemble the participants in the pivotal trials that established the combination. Advanced urothelial carcinoma commonly affects older adults, many of whom have reduced renal function because of age, previous surgery, urinary obstruction, or other chronic disease. Some have received earlier chemotherapy or immunotherapy, while others begin treatment with extensive metastatic disease and limited physical reserve. Observational cohorts cannot replace randomized comparisons because treatment decisions are not assigned by chance and may be influenced by disease severity or physician preference. However, they can reveal how treatment selection, dose management, and adverse-event monitoring function in the environment where most patients actually receive care.
The GUARDIANS results also contribute to a broader shift in the therapeutic logic of urothelial cancer. Instead of relying exclusively on sequential treatment—first chemotherapy, then immunotherapy, followed by a targeted agent—clinicians increasingly use biologically complementary combinations earlier in the disease course. The rationale is to expose cancer cells to multiple pressures before resistant clones become dominant. Yet combination therapy also raises an important clinical question: does improved tumor control come at the cost of tolerability? Real-world evidence can help answer that question by documenting how often patients require modifications, whether toxicity accumulates over time, and which baseline characteristics may identify people more likely to benefit or experience complications.
For patients and physicians, the practical message is not that enfortumab vedotin plus pembrolizumab is universally suitable, but that it has become a significant treatment option whose value depends on careful selection and active monitoring. Before and during therapy, clinicians may need to assess blood glucose, neurologic symptoms, skin changes, vision, liver function, thyroid activity, and signs of immune-mediated inflammation. Early recognition can be decisive: neuropathy may require dose adjustment, severe rash may demand interruption, and immune-related organ injury may need prompt immunosuppression. The regimen’s effectiveness must therefore be considered alongside the patient’s performance status, comorbidities, previous treatment exposure, goals of care, and ability to attend frequent monitoring visits.
As the GUARDIANS cohort adds evidence from routine practice, it strengthens the case for continuing to study how this dual-action treatment performs across different populations and health systems. Future research will need to clarify which molecular features predict response, whether specific metastatic sites behave differently, how long treatment should continue, and how the combination compares with emerging antibody–drug conjugates and other targeted therapies. Long-term follow-up will also be important for understanding delayed immune toxicities, persistent neuropathy, and outcomes after treatment discontinuation. For now, the multi-institutional experience places enfortumab vedotin plus pembrolizumab among the most consequential developments in advanced urothelial carcinoma, while emphasizing that the success of precision oncology depends not only on attacking the cancer, but also on managing the patient.
Subject of Research: Effectiveness and safety of enfortumab vedotin plus pembrolizumab in a real-world population with urothelial carcinoma.
Article Title: Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS)
Article References: Published in Cancer Immunology, Immunotherapy; DOI: 10.1007/s00262-026-04448-2
Image Credits: AI Generated
DOI: 10.1007/s00262-026-04448-2
Keywords: Urothelial carcinoma, bladder cancer, enfortumab vedotin, pembrolizumab, antibody–drug conjugate, immune checkpoint inhibitor, Nectin-4, PD-1, real-world evidence, GUARDIANS cohort, cancer immunotherapy, treatment safety
